You are here: Industry Insights > RedHill Biopharma

News List

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant prnewswire
August 27, 2021
RedHill Biopharma Ltd. today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations.
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib prnewswire
July 20, 2021
RedHill Biopharma Ltd. today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib prnasia
January 04, 2021
RedHill Biopharma Ltd. announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with COVID-19 pneumonia demonstrated positive safety and efficacy signals.
RedHill Biopharma Initiates Study of RHB-204 for NTM Disease americanpharmaceuticalreview
December 08, 2020
RedHill Biopharma has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) ...
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 prnasia
November 30, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib.
RedHill Biopharma's Second COVID-19 Candidate Cleared by FDA for Phase 2/3 Study americanpharmaceuticalreview
November 26, 2020
RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic COVID-19 ...
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease prnasia
November 20, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered ...
RedHill Biopharma to initiate Phase II/III trial of Covid-19 candidate pharmaceutical-technology
November 19, 2020
RedHill Biopharma is set to start the Phase II/III study evaluating orally administered RHB-107 (upamostat) in patients with symptomatic Covid-19 who do not require hospitalisation.
RedHill Biopharma Ramps-Up Manufacturing of Opaganib contractpharma
October 16, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, currently in global Phase 2/3 and ...
Redhill expands manufacturing for COVID-19 candidate pharmatimes
October 16, 2020
Redhill Biopharma has announced partnerships with two specialist pharmaceutical manufacturers in Europe and Canada to increase manufacturing for its COVID-19 candidate opaganib.

Previous page 1 2 3 Next page